Plasma Proteomics Identify Biomarkers Predicting Parkinson’s Disease up to 7 Years Before Symptom Onset
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

Plasma Proteomics Identify Biomarkers Predicting Parkinson’s Disease up to 7 Years Before Symptom Onset

A recent study found that 23 different proteins may help predict Parkinson’s disease (PD) and help differentiate people who may develop PD. The study also discovered that people with isolated REM Sleep Behavior Disorder (iRBD) had inflammatory blood markers suggesting the role of inflammation in the development of PD.

Read More
Is Sleep the Ultimate Brainwasher? 🧼🧠
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

Is Sleep the Ultimate Brainwasher? 🧼🧠

Researchers at Washington University School of Medicine discovered that during sleep, brain cell activity generates fluid movement that clears debris from the brain.

This process, driven by synchronized neural activity producing rhythmic waves, is crucial for removing metabolic waste, potentially offering new approaches to treating neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Read More
From “Fits” to Parkinson’s Disease
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

From “Fits” to Parkinson’s Disease

NAPS Investigator, Alon Avidan, MD, and a team of researchers measured the extent of diagnostic delay and identified common misdiagnoses. The range of initial diagnoses given at time of presentation included night terrors, nightmares, anxiety/panic, severe obstructive sleep apnea, Parkinson’s disease, and foodborne illness.

Read More
Heart Rate Variability During Sleep in Participants with Comorbid Traumatic Brain Injury, Post-Traumatic Stress Disorder, and RBD
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

Heart Rate Variability During Sleep in Participants with Comorbid Traumatic Brain Injury, Post-Traumatic Stress Disorder, and RBD

NAPS Investigator, Miranda Lim, MD, Hannah Cunningham, and a team of researchers from Oregon Health & Science University conducted a study to compare heart rate variability during sleep in patients with both RBD and neurotrauma (RBD+NT) in comparison to only RBD, only neurotrauma, and controls.

Read More
Annual International RBD Study Group Meeting | June 2024
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

Annual International RBD Study Group Meeting | June 2024

The annual International RBD Study Group meeting took place in the United Kingdom in June.

Several NAPS investigators and support teams attended and contributed to leading discussions for the event. They highlighted advancements in clinical research, discussed research design and outcomes, and shared updates from the NAPS study.

Read More
The First Person to be Diagnosed with RBD | CNN
Kaleidoscope Management Group Kaleidoscope Management Group

The First Person to be Diagnosed with RBD | CNN

Dr. Carlos Schenck, NAPS Scientific Advisory Board member and physician who first described RBD, discusses the importance of seeking medical evaluation for acting out dreams.

Read More
REM Sleep Behavior Disorder (RBD): Personal Perspectives and Research Priorities
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

REM Sleep Behavior Disorder (RBD): Personal Perspectives and Research Priorities

Dr. Carlos Schenck from the Minnesota Regional Sleep Disorder Center recently published a paper that offers a historical and personal perspective on REM Sleep Behavior Disorder (RBD) since its original discovery in 1985. As we approach the 40th anniversary of this discovery, Dr. Schenck's insights shed light on the significant milestones achieved following his initial observation in 1986.

Read More
High-Intensity Exercise Can Reverse Neurodegeneration in Parkinson’s Disease
Industry Updates Kaleidoscope Management Group Industry Updates Kaleidoscope Management Group

High-Intensity Exercise Can Reverse Neurodegeneration in Parkinson’s Disease

A new study suggests that high-intensity exercise may not only slow down but also potentially reverse neurodegeneration in Parkinson’s disease by preserving and enhancing dopamine-producing neurons. This finding is significant as it demonstrates, for the first time via brain imaging, that intense exercise can positively alter the brain's biology in Parkinson’s patients.

Read More
RBD Behavior Spectrum
Kaleidoscope Management Group Kaleidoscope Management Group

RBD Behavior Spectrum

RBD is characterized by the loss of normal muscle atonia during REM sleep, leading to the physical enactment of dreams. The spectrum of behaviors exhibited by individuals with RBD can vary widely, ranging from mild movements to more severe and potentially dangerous actions.

Read More
It's Imperative to Prioritize Safety Measures in RBD Sleeping Environments
Kaleidoscope Management Group Kaleidoscope Management Group

It's Imperative to Prioritize Safety Measures in RBD Sleeping Environments

Safety is often overlooked when discussing REM Sleep Behavior Disorder (RBD), yet it remains crucial. Undiagnosed RBD poses risks beyond sleep disturbances, extending to potential harm to oneself or others. Here are specific suggestions to optimize safety in the setting of REM Sleep Behavior Disorder.

Read More
What is Frontotemporal Dementia?
Kaleidoscope Management Group Kaleidoscope Management Group

What is Frontotemporal Dementia?

As the name suggests, Frontotemporal dementia (FTD) affects the frontal lobe and/or temporal lobes of the brain. Signs and symptoms vary, depending on which part of the brain is atrophying, or shrinking. Genetic mutations and dysfunctional proteins in the brain have been linked to FTD.

Read More
A Neurological Disease Paradigm Shift
Kaleidoscope Management Group Kaleidoscope Management Group

A Neurological Disease Paradigm Shift

In a paper published in The Lancet Neurology, a group of scientists, including NAPS Co-Investigator, Ronald Postuma, MD, MSc (McGill), argue that developing effective treatments for Parkinson’s disease demands a new way of classifying the disease for research purposes, one based not on clinical diagnosis but biology. The authors have called their biological model “SynNeurGe”.

Read More